LINKER-MM1: HRQoL outcomes with linvoseltamab for RRMM

Results from an analysis of the phase I/II LINKER-MM1 trial (NCT03761108), evaluating patient-reported health-related quality of life (HRQoL) in 117 patients with triple-class-exposed relapsed/refractory multiple myeloma (RRMM) treated with linvoseltamab, were published in Blood Neoplasia by Hoffman et al. Patient-reported HRQoL was assessed at baseline, Week 4, and every 4 weeks thereafter using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), the EORTC 20-item MM module (QLQ-MY20), and the EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L).

Key data: Nominally statistically significant improvements from baseline were observed across all scales, including Global Health Status/Quality of Life (GHS/QoL; least squares [LS] mean change, 7.0), social functioning (10.4; clinically meaningful), pain (−10.2; clinically meaningful), fatigue (−7.4), future perspective (FP; 11.9; clinically meaningful), and EQ-5D-3L visual analog scale (VAS; 8.0). Improvements in GHS/QoL were observed from Week 12 and in fatigue and pain from Week 16; these were largely sustained through Week 104, with pain reaching the clinically meaningful threshold at Week 20. Among treatment responders (70.9%), improvements were observed across all scales, with clinically meaningful improvements in social functioning (10.9), pain (−11.6), and FP (11.9). In contrast, nonresponders reported numeric worsening on most scales.

Key learning: Linvoseltamab treatment was associated with improvements in patient-reported HRQoL in patients with triple-class-exposed RRMM, with clinically meaningful improvements in social functioning, pain, and FP. HRQoL improvements were more pronounced among treatment responders than nonresponders.